Prohibiting Conflicts of Interest at the NIH

As scientists at the National Institutes of Health, we share the belief of director Elias Zerhouni and others, including Congress and the US public, that any financial conflict of interest at the agency is unacceptable and should be absolutely prohibited by regulations.

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

As scientists at the National Institutes of Health, we share the belief of director Elias Zerhouni and others, including Congress and the US public, that any financial conflict of interest at the agency is unacceptable and should be absolutely prohibited by regulations. We also recognize that some serious conflict-of-interest abuses have occurred at the NIH, which we find appalling and regrettable. However, we differ on the corrective measures imposed. These measures have gone far beyond conflict-of-interest issues, invaded privacy, and threatened to make the NIH unattractive to the best scientists, who are the foundation of its excellence.

The interim final regulations proposed by the Department of Health and Human Services (HHS) and by the NIH administration rest on two faulty assumptions: first, that every financial interest is a conflict of interest, and second, that comprehensive prohibitions are administratively easier and more efficient. This "ban every financial interest" approach leads to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies